VopF, a type III effector protein, has been identified as a contributory factor to the intestinal colonization of type III secretion system-positive, non-O1, non-O139 Vibrio cholerae strains. To gain more insight into the function of VopF, a yeast model was developed. Using this model, it was found that ectopic expression of VopF conferred toxicity in yeast.
Reduced vancomycin (VAN) susceptibility in clinical Clostridioides difficile isolates is correlated with poor clinical outcomes. However, factors associated with infection with these strains are unknown. The goal of this study was to determine risk factors for reduced VAN susceptibility among clinical isolates of C. difficile. This multicenter cohort study included adults with C. difficile infection (CDI) between 2016-21. Clinical C. difficile isolates underwent agar dilution VAN susceptibility testing and ribotyping. Reduced susceptibility was defined as a minimum inhibitory concentration (MIC) > 2 µg/mL. Medical charts were reviewed for host, pathogen, and hospital characteristics and assessed for predictors of reduced VAN susceptibility. Five hundred and ninety-four hospitalized patients with CDI between 2016-21 (female: 57%, >65 years old: 55%, white/non-Hispanic: 59%, non-severe CDI episode: 53%) were identified. Of 594 isolates, 173 (29%) had reduced VAN susceptibility (MIC50: 2 µg/mL, MIC90: 4 µg/mL). In multivariable analysis, ribotype (RT) 027 (odds ratio [OR]: 13.4; 95% confidence interval [CI]: 7.7-23.4; p<0.0001) and RT 255 (OR: 2.9; 95% CI: 1.4-6.1; p=0.005) were positively associated with reduced VAN susceptibility while RT 014-020 (OR: 0.41; 95% CI: 0.21-0.80; p=0.0092) was more likely to be susceptible to VAN. The prevalence of strains with reduced VAN susceptibility increased over time (p=0.0163). No patient- or hospitalization-specific variable predicted infection with reduced susceptibility strain. Certain ribotypes, including RT 027, were the sole independent risk factors for reduced VAN susceptibility. Increased clinical surveillance of these strains, especially RT 027, and their antibiotic susceptibly is warranted to inform prescribing practices.
28 February 2013 in Microbiology Resource Announcements
Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stems from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical trial results for recent antibiotic candidates, underscores the urgent need for novel CDI antibiotics. To this end, we investigated C. difficile enoyl ACP reductase ( Cd FabK), a crucial enzyme in de novo fatty acid synthesis, as a drug target for microbiome-sparing antibiotics. To test this concept, we evaluated the efficacy and in vivo spectrum of activity of the phenylimidazole analog 296, which is validated to inhibit intracellular Cd FabK. Against major CDI-associated ribotypes 296 had an Minimum inhibitory concentration (MIC 90 ) of 2 µg/mL, which was comparable to vancomycin (1 µg/mL), a standard of care antibiotic. In addition, 296 achieved high colonic concentrations and displayed dosed-dependent efficacy in mice with colitis CDI. Mice that were given 296 retained colonization resistance to C. difficile and had microbiomes that resembled the untreated mice. Conversely, both vancomycin and fidaxomicin induced significant changes to mice microbiomes, in a manner consistent with prior reports. Cd FabK, therefore, represents a potential target for microbiome-sparing CDI antibiotics, with phenylimidazoles providing a good chemical starting point for designing such agents.
Clostridioides difficile is a leading cause of antibiotic-associated diarrhea, with pathogenesis driven primarily by the glucosylating toxins TcdA and TcdB. Traditionally, toxin gene expression has been explained through regulation of the pathogenicity locus by global transcriptional regulators that integrate nutrient availability, growth phase, and environmental signals. While this framework provides a foundation for understanding toxin regulation, recent advances have broadened this perspective to include diverse metabolic and physiological inputs, including carbon and amino acid metabolism, metal ion homeostasis, redox balance, and cellular energy status. Collectively, these factors suggest that toxin gene expression is a dynamic emergent property that reflects a high level of integration of metabolic and physiological networks. In this minireview, we discuss canonical mechanisms of toxin regulation alongside new insights that highlight population heterogeneity, energy demand conflicts, metabolic constraints, purine metabolism, and cross-regulatory networks linking sporulation and virulence. We further examine discoveries from small-molecule chemical genetics demonstrating that perturbation of metabolic pathways can suppress toxin biosynthesis without substantially affecting bacterial viability. Together, these findings redefine toxin regulation as a systems-level process in which metabolic and physiological states mediate toxin production and contribute to phenotypic heterogeneity. Elucidating these networks may reveal promising targets for the development of anti-virulence strategies for C. difficile infection.